High-Select™ 去除离心柱
Invitrogen17万+抗体限时买二赠一，靶点广，灵活用！
High-Select™ 去除离心柱
High-Select™ 去除离心柱
High-Select™ 去除离心柱
引用和文献 (8)
Thermo Scientific™

High-Select™ 去除离心柱

Thermo Scientific High Select HSA/免疫球蛋白去除树脂可减少人血浆样品中的高丰度白蛋白和抗体组分，有助于为质谱分析或 1D 或 2D 电泳制备样品。树脂以方便的一次性微型离心柱形式提供，可用于处理了解更多信息
Have Questions?
更改视图buttonViewtableView
货号数量产品类型纯化目标
A3637024柱小型离心柱Top14 Abundant Protein
A363656柱小型离心柱HSA/Immunoglobulin
A3636624柱小型离心柱HSA/Immunoglobulin
A3636710柱小型离心柱HSA/Immunoglobulin
A3636850 mL树脂HSA/Immunoglobulin
A3637110柱小型离心柱Top14 Abundant Protein
A3637250 mL树脂Top14 Abundant Protein
A363696柱小型离心柱Top14 Abundant Protein
货号 A36370
价格（CNY)
7,263.00
飞享价
Ends: 31-Dec-2025
9,404.00
共减 2,141.00 (23%)
Each
添加至购物车
数量:
24柱
产品类型:
小型离心柱
纯化目标:
Top14 Abundant Protein
价格（CNY)
7,263.00
飞享价
Ends: 31-Dec-2025
9,404.00
共减 2,141.00 (23%)
Each
添加至购物车
Thermo Scientific High Select HSA/免疫球蛋白去除树脂可减少人血浆样品中的高丰度白蛋白和抗体组分，有助于为质谱分析或 1D 或 2D 电泳制备样品。树脂以方便的一次性微型离心柱形式提供，可用于处理 10 µL 样品。

HSA/IgG 去除树脂的特点包括：
•灵活 — 针对处理 10 µL 人血浆样品而调整和优化的微型柱形式
•优化 — 可去除 >95% 的 IgG 和 >95% 的白蛋白
•快速 — 在约10分钟内处理样品
•经济 — 极具性价比的离心柱针对单次使用定价
•减少差异性 — 一次性使用可防止蛋白残留和实验差异

High Select HSA/免疫球蛋白去除树脂使用高特异性固定化抗 HSA 和抗免疫异球蛋白抗体（IgG、IgA、IgM、IgD 和 IgE）去除血清和血浆中的人血清白蛋白 (HSA) 以及所有主要亚类免疫球蛋白。该树脂以经济方便的离心柱形式提供，专门设计用于一步处理和单次使用。

存在高浓度白蛋白和 IgG（可占总血清蛋白的 70% 以上）时，人体液分析通常会变得复杂。去除这些蛋白质通常对于低丰度蛋白的研究来说至关重要。High Select HSA/免疫球蛋白去除树脂能去除超过 95% 的 HSA 和 95% 的 IgG。将样品上样至预填充的一次性离心柱中，在大约10分钟内进行处理。去除高丰度蛋白有助于检测样品中的低丰度蛋白并通过质谱或 1D 或 2D 凝胶电泳进行后续鉴定。

推荐产品
High Select Top14 高丰度蛋白去除微型离心柱
High Select Top14 高丰度蛋白去除树脂
TMT10plex 同量异序标记试剂套件，3 x 0.8 mg
For Research Use Only. Not for use in diagnostic procedures.
规格
最终产品类型蛋白质
适用于（设备）质谱仪
标签或染料未标记
纯化目标Top14 Abundant Protein
数量24柱
运输条件湿冰
工作流程步骤蛋白去除
产品规格微型离心柱
产品线High Select
产品类型小型离心柱
原始材料血浆，血清, Serum
Unit SizeEach
内容与储存
储存在 2–8°C 下。

常见问题解答 (FAQ)

Can I use the High Select Top14 Abundant Protein Depletion Midi Spin Columns to deplete proteins from rodent samples?

The High Select Top14 Abundant Protein Depletion Midi Spin Columns have only been validated for human samples. We do not recommend using them for protein depletion in rodent samples. For protein depletion in rodent samples, we recommend the following multi-species depletion resins:

  • CaptureSelect MultiSpecies Albumin Depletion Product (Cat. No. 191085305)
  • Pierce Albumin Serum Depletion Kits (Cat. No. 89875)


    • Find additional tips, troubleshooting help, and resources within our Protein Purification and Isolation Support Center.

After depletion of abundant proteins from my sample, I still see albumin and other abundant proteins after LC-MS analysis. Did the depletion work?

Depletion does not remove all abundant proteins from the sample. Even with 99% depletion of a specific plasma protein, highly abundant proteins will still be the most abundant proteins in the sample detected by MS analysis. However, depletion significantly decreases the most abundant plasma proteins enabling identification of lower abundant proteins.

Find additional tips, troubleshooting help, and resources within our Mass Spectrometry Support Center.

How do I proceed to downstream mass spec sample preparation after abundant plasma protein depletion?

After the depletion, samples are significantly diluted in buffer. Depleted samples should be concentrated by speed vac drying, solvent precipitation, or diafiltration. Samples dried using a speedvac are directly compatible with the EasyPep kit chemistry after resuspension using the Lysis Solution.

Find additional tips, troubleshooting help, and resources within our Mass Spectrometry Support Center.

What is the maximum loading capacity for the High Select Depletion columns?

Mini columns can deplete up to 10 µL (600 µg) of plasma or serum; midi columns can deplete up to 100 µL (6000 µg) of plasma or serum.

Find additional tips, troubleshooting help, and resources within our Mass Spectrometry Support Center.

What is the percentage of albumin that is removed using abundant protein depletion columns?

More than 99% of albumin can be depleted when columns use the recommended sample to resin ratio.

Find additional tips, troubleshooting help, and resources within our Mass Spectrometry Support Center.

View all High-Select™ 去除离心柱 FAQs

引用和文献 (8)

引用和文献
Abstract
Integrated proteomics reveals brain-based cerebrospinal fluid biomarkers in asymptomatic and symptomatic Alzheimer's disease.
Authors:Higginbotham L,Ping L,Dammer EB,Duong DM,Zhou M,Gearing M,Hurst C,Glass JD,Factor SA,Johnson ECB,Hajjar I,Lah JJ,Levey AI,Seyfried NT
Journal:Science advances
PubMed ID:33087358
Alzheimer's disease (AD) lacks protein biomarkers reflective of its diverse underlying pathophysiology, hindering diagnostic and therapeutic advancements. Here, we used integrative proteomics to identify cerebrospinal fluid (CSF) biomarkers representing a wide spectrum of AD pathophysiology. Multiplex mass spectrometry identified ~3500 and ~12,000 proteins in AD CSF and brain, respectively. Network ... More
METTL16 inhibits pancreatic cancer proliferation and metastasis by promoting MROH8 RNA stability and inhibiting CAPN2 expression - experimental studies.
Authors:Yi T,Wang C,Ye X,Lin J,Lin C,Qin F,Yang W,Ye Y,Ning D,Lan J,Li H,Luo C,Ma J,Wei Z
Journal:International journal of surgery (London, England)
PubMed ID:39434688
BACKGROUND: N6-methyladenosine (m6A) modification plays a crucial role in the progression of various cancers, including pancreatic cancer, by regulating gene expression. However, the specific mechanisms by which m6A affects pancreatic cancer metastasis remain unclear. This study aims to elucidate the role of METTL16, an m6A writer gene, in regulating core ... More
Proteomic profiling identifies SPP1 associated with rapidly progressive interstitial lung disease in anti-MDA5-positive dermatomyositis.
Authors:Qiu Y,Feng X,Liu C,Shi Y,Xu L,You H,Wang L,Lv C,Wang F,Tan W
Journal:Arthritis research & therapy
PubMed ID:38167532
BACKGROUND: Anti-melanoma differentiation-associated gene five antibody positive (MDA5(+)) dermatomyositis (DM) is significantly associated with rapidly progressive interstitial lung disease (RP-ILD). Early detection of RP-ILD remains a major challenge. This study aims to identify and validate prognostic factors for RP-ILD in MDA5(+) DM patients. METHODS: Plasma samples from 20 MDA5(+) DM ... More
Enhancing Proteomics Quality Control: Insights from the Visualization Tool QCeltis.
Authors:Vegesna M,Sundararaman N,Bharadwaj A,Washington K,Pandey R,Haghani A,Chazarin B,Binek A,Fu Q,Cheng S,Herrington D,Van Eyk JE
Journal:Journal of proteome research
PubMed ID:39992359
Large-scale mass-spectrometry-based proteomics experiments are complex and prone to analytical variability, requiring rigorous quality checks across each step in the workflow: sample preparation, chromatography, mass spectrometry, and the bioinformatics stages. This includes quality control (QC) measures that address biological and technical variation. Most QC approaches involve detecting sample outliers and ... More
Tandem mass tag-based quantitative proteomic profiling identifies candidate serum biomarkers of drug-induced liver injury in humans.
Authors:Ravindra KC,Vaidya VS,Wang Z,Federspiel JD,Virgen-Slane R,Everley RA,Grove JI,Stephens C,Ocana MF,Robles-Díaz M,Isabel Lucena M,Andrade RJ,Atallah E,Gerbes AL,Weber S,Cortez-Pinto H,Fowell AJ,Hussaini H,Bjornsson ES,Patel J,Stirnimann G,Verma S,Elsharkawy AM,Griffiths WJH,Hyde C,Dear JW,Aithal GP,Ramaiah SK
Journal:Nature communications
PubMed ID:36869085
Diagnosis of drug-induced liver injury (DILI) and its distinction from other liver diseases are significant challenges in drug development and clinical practice. Here, we identify, confirm, and replicate the biomarker performance characteristics of candidate proteins in patients with DILI at onset (DO; n = 133) and follow-up (n = 120), acute non-DILI at onset ... More
View all High-Select™ 去除离心柱 citations